Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
681-700 of 3,900 trials

Guselkumab for Pediatric Crohn’s Disease

We are studying the safety and effectiveness of guselkumab in children with moderately to severely active Crohn’s disease. This trial aims to see how well the treatment works after initial positive responses.

Crohn's Disease1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

New Surgical Treatment for Wet AMD: Vitrectomy and TPA

We are studying a new surgical approach for people with submacular hemorrhage caused by wet AMD. This trial compares it to the standard treatment to see if it improves vision and eye health.

Exudative Age-Related Macular Degeneration1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Bronchiectasis: Comparing Antibiotic Treatments for PA Infection

We are studying two antibiotic regimens to see which is more effective for adults with bronchiectasis and early Pseudomonas aeruginosa infections. This research may help improve treatment options for these patients.

Bronchiectasis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

Recurrent Pericarditis in Children: Anakinra vs. Steroids

We are studying whether Anakinra is more effective than steroids for controlling recurrent pericarditis in children who haven't responded to other treatments. This trial aims to help improve care for young patients facing this condition.

Pericarditis3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyRheumatology

Chronic Open-Angle Glaucoma: Preservative-Free Bimatoprost Eye Drops

We are comparing a new preservative-free eye drop to a standard treatment for patients with chronic open-angle glaucoma or ocular hypertension. The goal is to see if the new formulation is effective and safe for managing eye pressure.

Chronic Open-angle GlaucomaOcular Hypertension3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOphthalmology

Chronic Pouchitis in Children: Vedolizumab IV Study

We are testing the intravenous medication vedolizumab in children with active chronic pouchitis to see if it helps them achieve remission. The study will also look at how well the treatment is tolerated and its overall effectiveness.

Pouchitis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Cystic Fibrosis: VX-522 Treatment Study

We are testing a new medication, VX-522, for adults with cystic fibrosis who do not respond to current treatments. The study will help us understand its safety and effectiveness compared to existing therapies.

Cystic Fibrosis6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPulmonology

Advanced Solid Tumors: STX-478 Treatment Study

We are investigating the effects of STX-478 alone and with other cancer drugs for people with advanced solid tumors. This study aims to see how well these treatments work together.

Breast CancerAdvanced Solid TumorsHead and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)Oncology

Advanced Solid Tumors: Debio 0123 Treatment

We are evaluating the safety and early anti-tumor effects of Debio 0123 in adults with advanced solid tumors. This study aims to see how well this treatment works compared to existing options.

Ovarian Epithelial CancerUterine CarcinomaSolid Tumor>2 yearsSafety phase (I)Oncology

Chronic Migraine: Dysport Treatment Study

We are studying whether Dysport can help reduce the number of migraine days in adults with chronic migraines. The trial will also look at its safety and overall effectiveness compared to a placebo.

Chronic Migraine1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteNeurology

Epcoritamab for Relapsed/Refractory Chronic Lymphocytic Leukemia

We are studying a new treatment called epcoritamab for patients with relapsed or refractory chronic lymphocytic leukemia and Richter's syndrome. The goal is to assess its safety and effectiveness, both alone and with other medications.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Colorectal Cancer: Post-Surgery Chemotherapy Study

We are investigating whether restarting chemotherapy after surgery helps patients with colorectal cancer that has spread to the liver live longer and stay cancer-free. This study compares different treatment approaches to find the best option.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Heart Failure: JTT-861 Medication Study

We are evaluating a new medication, JTT-861, for individuals with heart failure with reduced ejection fraction. The study aims to see if it is safe and effective in improving heart function.

Heart Failure with Reduced Ejection FractionEfficacy phase (II)Investigational MedicinesCost ReimbursementCardiologyInternal Medicine

Advanced Solid Tumors: GRWD5769 Treatment Study

We are testing the safety and effectiveness of GRWD5769 alone and with cemiplimab in patients with advanced solid tumors. This study aims to find out how well these treatments work and their tolerability.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Sickle Cell Pain Relief: Intranasal Sufentanil Study

We are investigating whether a new nasal spray for pain relief helps children with severe sickle cell pain crises feel better faster than standard treatments. This study aims to improve pain management in pediatric emergency care.

Vaso-Occlusive Crisis>2 yearsConfirmation phase (III)Investigational MedicinesHematologyInternal MedicinePediatrics

Fecal Microbiota Transplantation for Axial Spondyloarthritis

We are studying whether fecal microbiota transplantation can improve symptoms in patients with axial spondyloarthritis who haven't responded to standard treatments. This trial compares the effects of FMT to a placebo treatment.

Axial Spondyloarthritis>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteGastroenterologyRheumatology

Sotatercept for Children with Pulmonary Artery Hypertension

We are studying the safety and effects of sotatercept in children aged 1 to under 18 with pulmonary artery hypertension. This research aims to improve treatment options for young patients already receiving standard care.

Pulmonary Arterial Hypertension3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyPulmonology

Cutaneous Lupus Erythematosus: Litifilimab Injections

We are studying the long-term safety and effects of Litifilimab injections for adults with active cutaneous lupus erythematosus who have not responded to other treatments. This research aims to see if it can improve symptoms and overall quality of life.

Skin Lupus (Cutaneous Lupus Erythematosus)>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Bomedemstat vs Best Available Therapy for Essential Thrombocythemia

We are studying a new treatment for patients with essential thrombocythemia who haven't responded to hydroxyurea. The trial aims to see if bomedemstat is safer and more effective than current therapies.

Essential Thrombocythemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Pediatric Cancer: Crizotinib Treatment Study

We are testing the safety and effectiveness of crizotinib, alone and with temsirolimus, for children with ALK, ROS1, or MET positive cancers. This study aims to find the best dose and understand how well these treatments work.

NeuroblastomaAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumors6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics